Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor

Eitemau Tebyg

• Intracavitary chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is not superior to TKI monotherapy in controlling malignant pleural effusion recurrence in EGFR-mutated lung cancer patients
  gan: Wang, Wenxian, et al.
  Cyhoeddwyd: (2019)
• Treatment and prognosis after progression in long-term responders to EGFR-tyrosine kinase inhibitor in advanced non-small cell lung cancer
  gan: Song, Zhengbo, et al.
  Cyhoeddwyd: (2016)
• Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation
  gan: Becker, Kevin, et al.
  Cyhoeddwyd: (2014)
• Clinical efficacy evaluation of tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations
  gan: Song X, et al.
  Cyhoeddwyd: (2017-06-01)
• Clinical efficacy evaluation of tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations
  gan: Song, Xinyu, et al.
  Cyhoeddwyd: (2017)